Alpha-1 Antitrypsin Deficiency: Treatment Beyond Augmentation Therapy

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Alpha-1 Antitrypsin Deficiency: Treatment Beyond Augmentation Therapy

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 9(4): 330-335.

Author(s): Amit Mahajan and D Kyle Hogarth.

Affiliation: Department of Pulmonary and Critical Care Medicine,5841 South Maryland, MC 6076, Chicago, IL 60637, USA.


Alpha-1-antitrypsin (AAT) deficiency is a debilitating disease characterized by progressive parenchymal lung destruction. Deficiency of AAT results in a protease-antiprotease imbalance with unregulated activity of neutrophil elastase (NE). This imbalance results in accelerated parenchymal lung damage and a subsequent decrease in pulmonary function. Repletion of AAT enzyme with augmentation therapy using human pooled AAT is the current focus of treatment for AAT deficiency. While augmentation is a cornerstone of therapy for individuals with AAT deficiency, practitioners must also maximize standard treatment for obstructive lung disease like chronic obstructive pulmonary disease (COPD) to provide improved quality of life in patients suffering from AAT deficiency. Interventions such as smoking cessation, inhaled medications, pulmonary rehabilitation, supplemental oxygen therapy, vaccinations, avoidance of environmental exposures, and prophylactic antibiotics are essential therapies for the management of AAT deficiency.


Alpha-1-antitrypsin, alpha-1-antitrypsin deficiency, alpha-1-antitrypsin deficiency treatment, augmentation therapy, smoking cessation, pulmonary rehabilitation, protease-antiprotease, neutrophil elastase, chronic obstructive pulmonary disease (COPD), prophylactic antibiotics, panacinar emphysema, PiZZ phenotype, PiMM phenotype, dyspnea, phlegm production, wheezing, Current American Thoracic Society (ATS), European Respiratory Society (ERS), beta-agonists, corticosteroids, ciliary dysfunction, mucous plugging, chemotaxis, Eosinophils, Nicotine replacement therapies (NRT), verenicline, instrumental activities of daily living (IADL), hypoxemia, oxygen therapy, Medical Research Council (MRC), Nocturnal Oxygen Treatment Trial (NOTT), aerosolized toxins, mycobacterium avium intracellulare (MAI), pseudomonas aeruginosa, Moxifloxacin, aspergillus fumigatus.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 9
Issue Number: 4
First Page: 330
Last Page: 335
Page Count: 6
DOI: 10.2174/1871523011009040330
Price: $58

Related Journals

Webmaster Contact: Copyright © 2016 Bentham Science